Alterations of Hepatic Metabolism in Chronic Kidney Disease via D-box-binding Protein Aggravate the Renal Dysfunction

Kengo Hamamura1, Naoya Matsunaga2, Eriko Ikeda1

  • 1From the Department of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8512, Japan, the Drug Innovation Research Center, Daiichi University of Pharmacy, Minami-ku, Fukuoka 815-8511, Japan.

Insights

Chronic kidney disease (CKD) causes serum retinol accumulation due to altered liver metabolism. Targeting D-box-binding protein (DBP) and retinol may prevent worsening kidney function in CKD patients.

Area of Science:

  • Nephrology
  • Metabolic pathways
  • Hepatology

Background:

  • Chronic kidney disease (CKD) is linked to elevated serum retinol, but mechanisms remain unclear.
  • The liver plays a central role in retinol metabolism, involving cytochrome P450 (CYP) enzymes.

Purpose of the Study:

  • To investigate the mechanisms behind serum retinol accumulation in CKD.
  • To explore the role of hepatic metabolism and specific proteins in this process.

Main Methods:

  • Utilized 5/6 nephrectomy (5/6Nx) mouse model to simulate CKD.
  • Performed microarray analysis to assess hepatic gene expression.
  • Investigated the impact of transforming growth factor-β1 (TGF-β1) and D-box-binding protein (DBP).

Main Results:

  • 5/6Nx mice exhibited altered hepatic metabolism and increased serum retinol.
  • Decreased hepatic expression of DBP was observed, affecting CYP genes like Cyp3a11 and Cyp26a1.
  • Anti-TGF-β1 antibody treatment ameliorated retinol metabolism and renal dysfunction.
  • Retinol accumulation induced renal apoptosis; a retinol-free diet reduced renal dysfunction.

Conclusions:

  • Altered hepatic metabolism, specifically reduced DBP expression, contributes to retinol accumulation in CKD.
  • TGF-β1 exacerbates renal dysfunction by downregulating DBP.
  • Therapeutic strategies targeting DBP and retinol metabolism show potential for managing CKD progression.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
304
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
609
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
334
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
936
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
574